Insiders Kancera AB

Equities

KAN

SE0015658570

Delayed Nasdaq Stockholm Other stock markets 06:46:33 2024-05-14 EDT			5-day change	1st Jan Change
1.77 ^SEK	+2.79%		+26.25%	-61.06%

05-08	Kancera AB Announces Executive Changes	CI
05-03	Kancera AB Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kancera AB Announces Executive Changes	05-08	CI
Kancera Names Successor to Outgoing Chief Medical Officer	23-09-01	MT
Kancera AB Appoints Markus Jerling as Chief Medical Officer	23-09-01	CI
Kancera CEO Moves to Chief Scientific Officer Role; Successor Named	23-05-26	MT
Kancera AB Appoints Thomas Olin as Executive Vice President and Chief Scientific Officer	23-05-26	CI
Kancera AB Appoints Peter Selin as New Chief Executive Officer, Effective from July 1 2023	23-05-26	CI
Kancera reports that the Swedish Medical Products Agency has approved the application to conduct the KANDOVA-study and that Dr. Hanjing Xie has been appointed to Chief Medical Officer	23-02-16	AQ
Kancera AB Appoints Peter Selin as Executive Vice President Corporate Development, Effective May 1, 2022	21-12-06	CI
Kancera AB Provides an Update on the Development of the Company's Pharmaceutical Project and Nominates A New Drug Candidate	21-04-21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW